FRANKFURT, Aug 4 (Reuters) - German biotech firm

BioNTech on Monday said that second-quarter revenues

more than doubled to 261 million euros ($302 million), driven

by higher revenues from its COVID-19 vaccine collaboration with

Pfizer ( PFE ).

The company's quarterly net loss came in at 387 million

euros, an improvement over a net loss of 808 million in the

year-earlier period, which at the time was burdened by

provisions for a settlement with the U.S. National Institutes of

Health over vaccine royalty payments.

Lower operating expenses also helped reduce the

second-quarter loss, it added.

BioNTech reiterated its guidance for 2025 revenues of 1.7

billion to 2.2 billion euros, down from 2.75 billion last year.

BioNTech in June agreed to acquire domestic peer CureVac ( CVAC )

in a $1.25 billion share deal, boosting its work on new

mRNA-based cancer treatments and quelling patent litigation

brought by the takeover target.

That was shortly after Bristol Myers Squibb ( BMY ) agreed

to pay up to $11.1 billion for rights to jointly develop

BioNTech's next-generation cancer immunotherapy.

($1 = 0.8654 euros)